Galectin-9, Recombinant, Human

Galectins comprise a family of multi- functional carbohydrate-binding proteins with specificity for N-acetyl-lactosamine-containing glycoproteins. At least 14 mammalian Galectins share structural similarities in their carbohydrate recognition domains (CRD), forming three groups. Full length Galectin-9 is a widely expressed 39kD tandem-repeat Galectin that contains two CRDs connected by a linker region. Progressive deletion within the linker region generates a 36kD isoform and a 35kD isoform. This recombinant protein corresponds to the Ecalectin isoform of human Galectin-9 and shares 70% and 73% aa sequence identity with mouse and rat Galectin-9, respectively. Galectin-9 exhibits a wide range of activities. All three isoforms function as eosinophil chemoattractants. This activity is destroyed by thrombin-mediated cleavage within the linker region of the long isoform, although the Ecalectin isoform is resistant to thrombin. Galectin-9 binds to carbohydrate moieties of IgE, thereby preventing immune complex formation, mast cell degranulation, and asthmatic and cutaneous anaphylaxis reactions. Independent of its lectin properties, Galectin-9 induces the maturation of dendritic cells which promote Th1 polarization. Galectin9 induces cellular apoptosis in part by direct binding to TIM-3. Its interaction with TIM-3 inhibits Th1 cell and CD8+ cytotoxic T cell responses and also promotes regulatory T cell differentiation and activity. Galectin-9 suppresses tumor cell metastasis by interfering with the associations between hyaluronic acid and CD44 and between VCAM-1 and Integrin a4b1. The Ecalectin isoform can also be expressed as an integral membrane protein and mediate the cellular efflux of urate. \n\nRecombinant protein corresponding to Ala2-Thr323 from human Galectin-9 expressed in E. coli (BAA31542).\n\nActivity:\n1. Measured by its ability to induce apoptosis of Jurkat human acute T cell leukemia cells. The ED50 for this effect is typically 1-5ug/ml.\n2. Measured by its ability to agglutinate human red blood cells. The ED50 for this effect is typically 2.5-12.5ug/ml.\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Reconstituted product is stable for 6 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

G1044-58

Size

50ug

Form

Supplied as a lyophilized powder from 20mM MOPS, 500mM sodium chloride, 0.5mM EDTA, 1mM DTT, 20mM Trehalose. Reconstitute in sterile ddH20 to 0.1mg/ml.

Purity

~95% (SDS-PAGE) Endotoxin: (same/less than)1EU/ug (LAL)

References

1. Yang, RY. et al. (2008) Expert Rev. Mol. Med. 10:e17. 2. Elola, M. T. et al. (2007) Cell. Mol. Life Sci. 64:1679. 3. Tureci, O. et al. (1997) J. Biol. Chem. 272:6416. 4. Chabot, S. et al. (2002) Glycobiology 12:111. 5. Matsumoto, R. et al. (2002) J. Immunol. 168:1961. 6. Sato, M. et al. (2002) Glycobiology 12:191. 7. Nishi, N. et al. (2006) Glycobiology 16:15C. 8. Niki, T. et al. (2009) J. Biol. Chem. 284:32344. 9. Dai, S.Y. et al. (2005) J. Immunol. 175:2974. 10. Seki, M. et al. (2007) Arthritis Rheum. 56:3968. 11. Zhu, C. et al. (2005) Nat. Immunol. 6:1245. 12. Sehrawat, S. et al. (2010) PloS Pathogens 6:e1000882. 13. Nobumoto, A. et al. (2008) Glycobiology 18:735. 14. LealPinto, E. et al. (2002) Am. J. Physiol. Renal Physiol. 283:F150. 15. Lu, L.H. et al. (2007) J. Biochem. 141:157. 16. Hadari, Y.R. et al. (2000) J. Cell Sci. 113:2385.